FINWIRES · TerminalLIVE
FINWIRES
$JNJ

$JNJ

79 stories mentioning JNJUpdated 11d ago

Every FINWIRES story that references JNJ, newest first.

What are analysts saying about JNJ?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on JNJ?

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.8%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Novartis (NVS) has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday. Novartis shares rose 0.5%.Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline, UBS said in a note. UBS assumed coverage of the stock with a buy rating and a $320 price target. Its shares rose 1.6%.Alumis (ALMS) shares jumped past 8%. The company's share price drop after the disappointing results of a phase 2b trial of envudeucitinib to treat systemic lupus erythematosus was likely an overreaction, Oppenheimer said in a note. Oppenheimer kept Alumis' outperform rating, while lowering the company's price target to $37 from $55.Telix Pharmaceuticals (TLX) said it completed patient enrollment for a phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting. Telix shares climbed 5.6%.

$ALMS$JNJ$NVS$TLX
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) increased 0.4%.In corporate news, Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline, UBS said in a note. UBS assumed coverage of the stock with a buy rating and a $320 price target. Its shares rose 1.3%.Alumis (ALMS) shares climbed 10%. The company's share price drop after the disappointing results of a phase 2b trial of envudeucitinib to treat systemic lupus erythematosus was likely an overreaction, Oppenheimer said in a note. Oppenheimer kept Alumis' outperform rating, while lowering the company's price target to $37 from $55.Telix Pharmaceuticals (TLX) said it completed patient enrollment for a phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting. Telix shares jumped 5.2%.

$ALMS$JNJ$TLX
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.8%.The iShares Biotechnology ETF (IBB) increased 0.6%.In corporate news, Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline, UBS said in a note. UBS assumed coverage of the stock with a buy rating and a $320 price target. Shares rose 1.5%.

$JNJ
Wire

Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says

Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline, UBS Securities said in a note Wednesday.Analysts said they have identified seven major franchises, each with more than $5 billion in potential revenue, creating a $30 billion to over $40 billion pipeline opportunity across immunology and oncology that could support growth well into the next decade.The company is expected to post revenue and earnings per share above consensus through 2030 to 2032, as growth accelerates from its historical 4% to 6% compound annual growth rate to 8% plus CAGR for the rest of the decade driven by a more diversified portfolio of blockbuster medicines, according to the note.The firm said it views Johnson & Johnson as "one of the cleanest stories in large-cap pharma," with no major loss of exclusivity issues in the near term.UBS Securities assumed coverage of Johnson & Johnson with a buy rating and a $320 price target.Price: $275.12, Change: $+3.93, Percent Change: +1.45%

$JNJ
Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat
US Markets

Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-than-expected fiscal first-quarter results.The company now anticipates adjusted earnings to be in a range of $5.94 to $6 per share for fiscal 2027, reflecting a higher bottom end versus the prior guidance of $5.90. The current consensus on FactSet is for non-GAAP EPS of $5.95.Organic revenue is pegged to grow by 7.3% to 7.8% for the ongoing fiscal year, compared with previous projections for an increase of 6.8% to 7.3%, according to the firm. The stock inclined 3.3% in the most recent premarket activity."We continue to make targeted investments in innovation, portfolio development, and commercial execution that will support sustainable long-term value creation," Chief Financial Officer Thierry Pieton said in a statement. "The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance."For the three months through July, Medtronic's adjusted EPS advanced to $1.45 from $1.26 the year before, topping the Street's view for $1.39. Revenue gained 14% to $9.76 billion, exceeding the average analyst estimate of $9.55 billion. Revenue also grew 14% on an organic basis.Last week, Needham said in an emailed client note that it expected Medtronic to top Wall Street's forecasts for the first quarter and raise its fiscal 2027 guidance amid new product launches and stable market growth.Revenue in the cardiovascular portfolio jumped 20% to $3.93 billion in the first quarter, led by a 30% gain in electrophysiology therapies. Sales in the neuroscience and medical surgical divisions rose 10% each to $2.68 billion and $2.28 billion, respectively. Diabetes revenue climbed 17% to $843 million."We are off to a strong start in fiscal 2027," Chief Executive Geoff Martha said. "The strength of our portfolio and pipeline gives us confidence in the opportunities ahead."Separately, Medtronic said it entered into a strategic partnership with Cornerstone Robotics under which it will invest $700 million in the surgical robotics company. The investment will give Medtronic the right to distribute Cornerstone Robotics' Sentire surgical system in certain markets outside the US where the platform is approved.Last month, Becton Dickinson (BDX) raised its full-year earnings guidance, while Abbott Laboratories (ABT) in July lifted its full-year earnings outlook and reported quarterly results above market estimates. Healthcare products conglomerate Johnson & Johnson (JNJ) also raised its guidance for 2026 in July.

$ABT$BDX$JNJ$MDT
Wire

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

Protagonist Therapeutics' (PTGX) future growth will hinge more on its wholly owned programs than on its newly approved partner therapy, with the company's first clinical readouts from its proprietary pipeline expected in H1 2027. Wedbush Securities said Monday in a report.Wedbush highlighted PN-8047, an oral version of rusfertide, a treatment recently approved for polycythemia vera and commercialized by Takeda Pharmaceutical (TAK). PN-8047 appears similarly potent and may move into a phase 2 study in 2027 if early safety and iron-lowering data are positive, the report said.Protagonist's cash position is strengthened by payments tied to rusfertide's regulatory approval, including a $200 million opt-out fee and a $75 million milestone, along with similar payments from Johnson & Johnson (JNJ) for icotyde, an oral anti-inflammatory drug being developed for psoriasis and other immune conditions, the report said.Wedbush maintained its outperform rating on Protagonist stock with a $173 price target.Price: $144.35, Change: $+0.02, Percent Change: +0.01%

$JNJ$PTGX$TAK
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) gained 1.5%.In corporate news, Jupiter Neurosciences (JUNS) shares surged past 16% after it said it priced a direct offering of 307,692 shares for gross proceeds of $2 million.Johnson & Johnson (JNJ) shares rose 1.3% after the firm said Friday Tecvayli plus daratumumab has been approved by the European Commission to treat adults with relapsed or refractory multiple myeloma.Arbutus Biopharma (ABUS) shares jumped past 9% after the firm said it plans to launch a tender offer to repurchase up to $230 million of its shares at between $5.00 and $5.75 per share.Health Catalyst (HCAT) shares fell 4.6% after Canaccord Genuity downgraded the stock to hold from buy and cut its price target to $1.80 from $3.

$ABUS$HCAT$JNJ$JUNS
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.8%.In corporate news, Johnson & Johnson (JNJ) shares rose 1.3% after the firm said Friday Tecvayli plus daratumumab has been approved by the European Commission to treat adults with relapsed or refractory multiple myeloma.Arbutus Biopharma (ABUS) shares jumped past 7% after the firm said it plans to launch a tender offer to repurchase up to $230 million of its shares at between $5.00 and $5.75 per share.Gossamer Bio (GOSS) shares were up 0.8% after the firm said it has agreed to sell up to $250 million of securities in a structured private placement to new and existing institutional investors.Werewolf Therapeutics (HOWL) and Ambros Therapeutics said they have struck an all-stock merger agreement to create a late-stage biotech company. Werewolf shares surged 108%.

$ABUS$GOSS$HOWL$JNJ
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate news, Johnson & Johnson (JNJ) shares rose 1.4% after the firm said Friday Tecvayli plus daratumumab has been approved by the European Commission to treat adults with relapsed or refractory multiple myeloma.

$JNJ
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
US Markets

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for the second quarter.For 2026, Merck now expects revenue of $66.3 billion and $67.3 billion, compared with its prior guidance of $65.8 billion to $67.0 billion and the FactSet-polled consensus of $66.86 billion. The company cut its full-year adjusted earnings estimate to a range of $2.66 and $2.76, from $5.04 to $5.16, to account for charges of $2.43 per share for the acquisition of Terns Pharmaceuticals (TERN). Analysts expect non-GAAP EPS of $2.79.For the June quarter, Merck's sales rose 5% year over year to $16.61 billion, topping the consensus of $16.37 billion. The company swung to a second-quarter non-GAAP loss $0.13 per share due to the Terns acquisition charge, from EPS of $2.13 a year earlier, while analysts expected a loss of $0.27.In May, the company announced completion of the acquisition of Terns and flagged the one-time charge."We delivered growth in the quarter led by continued strength in oncology and animal health, along with increasing contributions from our diverse and compelling new products across an array of therapeutic areas," Merck Chief Financial Officer Caroline Litchfield said at an earnings call, according to a FactSet transcript.Pfizer narrowed its full-year revenue outlook to between $60.5 billion to $62.5 billion from the previous range of $59.5 billion to $62.5 billion, reflecting a $500 million increase at the midpoint. The company maintained its adjusted EPS guidance of $2.80 to $3. At midpoint the estimates are both below the consensus forecasts of $61.77 billion and $2.94, respectively.Pfizer's second-quarter sales grew 3% year over year to $15.03 billion, while analysts projected $14.4 billion. Adjusted EPS fell to $0.77 from $0.78 a year earlier but exceeded the Street's $0.68 forecast."Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength," Pfizer CEO Albert Bourla said in a statement.Last week, AbbVie (ABBV) lowered its full-year earnings guidance to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected second-quarter results.Last month, Johnson & Johnson (JNJ) raised its full-year outlook after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. Bristol-Myers Squibb (BMY) also raised its full-year guidance after reporting second-quarter results.Merck shares of were advancing by 0.3% in Tuesday morning trade, with the stock up 22% so far this year. Pfizer was down 0.4% intraday and is up about 0.1% since the start of the year.Price: $128.40, Change: $+0.63, Percent Change: +0.49%

$ABBV$APGE$BMY$JNJ$MRK$PFE$TERN
Wire

Raymond James Adjusts Price Target on Johnson & Johnson to $280 From $265, Maintains Outperform Rating

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $275.81, according to analysts polled by FactSet.Price: $253.95, Change: $-2.40, Percent Change: -0.94%

$JNJ
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
Wire

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected second-quarter results.The biopharmaceutical company now expects earnings per share of $13.87 to $14.07 for 2026, compared with its prior estimate of $13.91 to $14.11. The updated guidance's midpoint of $13.97 falls short of the FactSet-polled consensus of $14.06.AbbVie expects the proposed acquisition of Apogee, which was announced last month and is expected to close in the third quarter, to be $0.14 dilutive this year. The all-cash transaction valued at about $10.9 billion will give AbbVie access to Apogee's portfolio of clinical-stage candidates currently in development for the treatment of inflammatory and immunological diseases, including potential atopic dermatitis therapy zumilokibart."That is more than offsetting our underlying overperformance," Chief Financial Officer Scott Reents said at an earnings call, according to a FactSet transcript, referring to the anticipated dilution.AbbVie's stock was down 1.3% intraday, trimming the year-to-date gain to about 11%.Adjusted EPS for the June quarter rose to $3.65 from $2.97 a year earlier, surpassing the consensus of $3.60. Net revenue grew 10% to $16.99 billion, while analysts expected $16.78 billion."AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement," Chief Executive Robert Michael said in the earnings release. "Based on our substantial momentum, AbbVie's long-term outlook remains very strong."Earlier this month, Johnson & Johnson (JNJ) raised its full-year outlook after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. On Thursday, Bristol-Myers Squibb (BMY) also raised its full-year guidance after reporting second-quarter results.AbbVie's immunology portfolio generated $8.79 billion in global sales during the second quarter, up 15% year over year, with Skyrizi and Rinvoq both delivering more than 20% growth in revenue to offset weak Humira sales.Global sales from the neuroscience segment jumped 20% to $3.23 billion, while revenue in the aesthetics portfolio increased 0.3% to $1.28 billion. Oncology portfolio sales fell 1.5% to $1.65 billion.The company expects third-quarter revenue of $17.2 billion, lower than the FactSet-polled consensus of $17.35 billion. Adjusted EPS for the ongoing quarter is expected between $3.84 and $3.88, compared with Wall Street's estimate of $3.87.Price: $253.60, Change: $-3.82, Percent Change: -1.48%

$ABBV$APGE$BMY$JNJ
Wire

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.7%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Xencor (XNCR) shares rose nearly 11% after the company said it has reached a settlement agreement with AstraZeneca (AZN) subsidiary Alexion Pharma International to resolve a commercial dispute over US royalties on Ultomiris. AstraZeneca shares were down 1.2%.Eli Lilly (LLY) expanded its collaboration with Resilience to invest $750 million as part of its effort to boost US production of Lilly's KwikPen injectable device for diabetes and obesity medicines, Resilience said Thursday. Lilly shares were down 4.4%.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to buy Sail for $2.58 billion. Johnson & Johnson shares fell 3.8%.Bausch Health (BHC) shares surged 26% after it reported higher Q2 results and raised its 2026 revenue outlook.Regeneron Pharmaceuticals (REGN) shares were up 6.3% after it reported higher Q2 results.

$AZN$BHC$JNJ$LLY$REGN$XNCR
Sectors

Sector Update: Healthcare Stocks Decline Thursday Afternoon

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.8%.The iShares Biotechnology ETF (IBB) was shedding 0.6%.In corporate news, Eli Lilly (LLY) expanded its collaboration with Resilience to invest $750 million as part of its effort to boost US production of Lilly's KwikPen injectable device for diabetes and obesity medicines, Resilience said Thursday. Lilly shares were down 4%.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to buy Sail for $2.58 billion. Johnson & Johnson shares fell 3.8%.Accuray (ARAY) shares surged 25% after it said late Wednesday it has entered into definitive agreements with TCW Asset Management, including a debt exchange deal, to strengthen its financial position and provide additional liquidity.

$ARAY$JNJ$LLY
Wire

Johnson & Johnson's Rybrevant Faspro Secures FDA Priority Review for Head, Neck Cancer Treatment

Johnson & Johnson (JNJ) has obtained priority review status from the US Food and Drug Administration for its supplemental biologics license application for Rybrevant Faspro, for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma, which is the most common form of head and neck cancer, the company said Thursday.The treatment, which consists of subcutaneous amivantamab and hyaluronidase-lpuj, aims to treat patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, according to a statement.The priority review status shortens the regulatory review timeline to about six months, the company said.Price: $255.08, Change: $-10.45, Percent Change: -3.94%

$JNJ
Sectors

Sector Update: Healthcare Stocks Decline Premarket Thursday

Healthcare stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 1.4% and the iShares Biotechnology ETF (IBB) 1.6% lower.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. Shares of Johnson & Johnson were down more than 2% pre-bell.Bristol-Myers Squibb (BMY) stock was down more than 1% even after the company posted higher Q2 non-GAAP earnings and revenue, and raised its 2026 outlook.Regeneron Pharmaceuticals (REGN) shares were up more than 1% after the company reported higher Q2 adjusted earnings and revenue.

$BMY$IBB$JNJ$REGN$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 1.5% and the iShares Biotechnology ETF (IBB) 0.4% lower.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. Shares of Johnson & Johnson were down more than 2% pre-bell.

$JNJ
Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device
US Markets

Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant.The medical device maker now expects 2026 adjusted earnings per share of $3.28 to $3.32, down from its previous outlook of $3.34 to $3.41. The FactSet-polled consensus is for $3.36.Full-year net sales are now projected to grow 5.5% to 6.5% from last year, compared with its prior growth estimate of 7% to 8.5% growth. Analysts in a FactSet survey are projecting sales of $21.59 billion, indicating a 7.6% year-over-year growth."Our guidance reduction is concentrated in two areas. First, Watchman, where the US market has slowed sharply and unexpectedly, primarily driven by compounding clinical evidence, which has impacted referral patterns," Chief Executive Mike Mahoney said during an earnings call, according to a FactSet transcript. "And second, (electrophysiology), where we did not anticipate the degree of competitive share movement we're now seeing in the US market."Watchman underperformed expectations in the second quarter, with US sales growing 3% organically, according to a slide deck. Electrophysiology revenue rose 9.1% globally, but was weighed down by competitive pressures in the US.Mahoney flagged a downbeat demand outlook for Watchman for 2026, with global sales likely to be flat to up low single digits."We anticipate that year-over-year concomitant (procedure) growth will materially slow in the second half due to higher comps from 2025," Mahoney said. "Our outlook does not anticipate any improvement in standalone procedural growth trends in the second half."Boston Scientific expects flat second-half global growth for electrophysiology in the US, Mahoney told analysts.Johnson & Johnson (JNJ) raised its full-year outlook earlier this month as its innovative medicine and medical device businesses drove a strong second quarter.For the third quarter, Boston Scientific projects adjusted EPS of $0.80 to $0.82 and net sales growth of 3% to 5%. Analysts are looking for $0.84 and $5.38 billion, respectively.The company reported June-quarter adjusted EPS of $0.86, up from $0.75 a year earlier and surpassing Wall Street's $0.83 estimate. Net sales grew 7.5% to $5.44 billion, while analysts expected $5.36 billion.Sales in the cardiovascular business increased 8.3% year over year to $3.62 billion. The MedSurg division delivered a 5.9% jump to $1.82 billion, led by a double-digit gain in neuromodulation.Boston Scientific's shares rose 0.7% intraday Wednesday, reversing course from earlier in the day. The stock has plunged 51% so far this year.Price: $46.43, Change: $+0.37, Percent Change: +0.80%

$BSX$JNJ
Insider Trading

Johnson & Johnson Insider Sold Shares Worth $5,792,686, According to a Recent SEC Filing

Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs, on July 20, 2026, sold 23,054 shares in Johnson & Johnson (JNJ) for $5,792,686. Following the Form 4 filing with the SEC, Broadhurst has control over a total of 23,003 common shares of the company, with 23,003 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/200406/000020040626000148/xslF345X05/wk-form4_1784669273.xml

$JNJ
Wire

Argus Lifts Johnson & Johnson Price Target to $290 From $275

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $272.43, according to analysts polled by FactSet.Price: $249.69, Change: $+2.67, Percent Change: +1.08%

$JNJ

Showing 1-20 of 79

Track with the FINWIRES app suite

FolioX
FolioX
Track JNJ in your portfolio
WheelAI
WheelAI
Analyze JNJ options with the wheel strategy
StockInsider
StockInsider
See market sentiment on JNJ